인쇄하기
취소

KFDA announces voluntary withdrawal of Zelmac

Published: 2007-04-06 06:56:00
Updated: 2007-04-06 06:56:00
The Korea Food and Drug Administration (KFDA) announced on April 2 that Novartis Korea has halted sales of Zelmac (tegaserod), its agent for irritable bowel syndrome and constipation, following suggestions of a small increase in ischemic events, including angina and stroke, in those taking the drug.

The company will voluntarily remove Zelmac from the market.

The ischemic events came to li...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.